Toll-like receptor 9 (TLR9) agonists have emerged as versatile modulators of innate immunity with the capacity to bridge to adaptive antitumour responses. By engaging endosomal TLR9 on plasmacytoid ...
A phase I study of allogeneic anti-CD19 CAR-T therapy for patients with CD19+ relapsed/refractory acute B-lymphoblastic leukemia. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results